Description

Moderna’s Cancer Vaccine Breakthrough Has A Bigger Test Ahead!

Moderna has moved into a very different phase of its post-pandemic story. Its shares surged after the Phase 3 INTerpath-001 melanoma study delivered a positive result for intismeran autogene, the individualized mRNA cancer therapy being developed with Merck and used alongside Keytruda. The study met its primary recurrence-free-survival endpoint and also succeeded on distant-metastasis-free survival in 1,137 patients with resected high-risk melanoma. Yet the market has already repriced the company before investors have seen the complete efficacy package. Moderna and Merck have not yet disclosed the detailed Phase 3 hazard ratios, absolute survival rates, subgroup results, or mature overall-survival data. The companies plan to present the full dataset at an upcoming international medical meeting and discuss potential filings with regulators.